Technical Analysis for DCPH - Deciphera Pharmaceuticals, Inc.
|Grade||Last Price||% Change||Price Change|
DCPH closed up 5.49 percent on Friday, January 19, 2018, on approximately normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
|See historical DCPH trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 19||New 52 Week Closing High||Bullish||0.00%|
|Jan 19||New 52 Week High||Strength||0.00%|
|Jan 19||Stochastic Reached Overbought||Strength||0.00%|
|Jan 19||Wide Bands||Range Expansion||0.00%|
|Jan 19||Overbought Stochastic||Strength||0.00%|
|Jan 19||Up 3 Days in a Row||Strength||0.00%|
|Jan 18||New 52 Week High||Strength||5.49%|
|Jan 18||Wide Bands||Range Expansion||5.49%|
|Jan 18||Overbought Stochastic||Strength||5.49%|
|Jan 17||Wide Bands||Range Expansion||9.97%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Deciphera Pharmaceuticals, LLC is a United-States based clinical-stage biopharmaceutical company. The Company provides treatment for cancer patients. The Company focuses on developing tumor-targeted and immuno-targeted kinase inhibitors. Its switch control inhibitor platform is engaged in producing kinase inhibitors with distinct profiles and anti-cancer effects. Its tumor-targeting therapies include DCC-2618. DCC-2618 is a pan-KIT and PDGFR alpha kinase switch control inhibitor in clinical development for the treatment of KIT and/or Platelet-derived growth factor receptor alpha-driven cancers, including gastrointestinal stromal tumors, glioblastoma multiforme and systemic mastocytosis. Its Immuno-Targeted Therapies include DCC-3014 and Rebastinib. DCC-3014 is a potent and highly-selective immunokinase inhibitor targeting colony stimulating factor receptor 1 (CSF1R). Rebastinib is a TIE2 inhibitor targeting TIE2 expressing macrophages. Rebastinib is in the clinical development stage.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more DCPH news...
|52 Week High||27.53|
|52 Week Low||15.15|
|200-Day Moving Average||0.0|
|50-Day Moving Average||20.5282|
|20-Day Moving Average||23.8725|
|10-Day Moving Average||25.393|
|Average True Range||1.6378|
|Chandelier Exit (Long, 3 ATRs )||22.6166|
|Chandelier Exit (Short, 3 ATRs )||20.9934|
|Upper Bollinger Band||28.518|
|Lower Bollinger Band||19.227|
|Percent B (%b)||0.89|
|MACD Signal Line||1.5936|
|Market Cap||876.98 Million|
|Num Shares||31.9 Million|
|Price-to-Earnings (P/E) Ratio||-1.71|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||30.34|
|Resistance 3 (R3)||30.04||28.78||29.86|
|Resistance 2 (R2)||28.78||28.05||28.93||29.70|
|Resistance 1 (R1)||28.13||27.60||28.46||28.43||29.54|
|Support 1 (S1)||26.22||26.14||26.55||26.52||25.40|
|Support 2 (S2)||24.96||25.69||25.11||25.24|
|Support 3 (S3)||24.31||24.96||25.08|
|Support 4 (S4)||24.61|